MedTrace Logo

Oral Cannabidiol Effect on Blood Pressure in Hypertensive Patients

NCT05346562 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-05-16

No results posted yet for this study

Summary

The objective of this randomized, placebo-controlled and crossover study is to extend the findings from the acute studies into more chronic administration of CBD in individuals with mild or moderate hypertension who are either untreated or receiving standard care therapy. The hypothesis is that the hypotensive effects of CBD will be apparent in both untreated and treated hypertension and reflected in improved vascular biomarkers and psychological well-being.

Conditions

Interventions

DIETARY_SUPPLEMENT

Cannabidiol

Cannabidiol tablets

DIETARY_SUPPLEMENT

Placebo

Cannabidiol-matched placebo tablets

Sponsors & Collaborators

  • Lexaria Bioscience Corp.

    collaborator INDUSTRY

  • University of British Columbia

    collaborator OTHER

  • University of Colorado, Denver

    collaborator OTHER

  • University of Split, School of Medicine

    lead OTHER

Principal Investigators

  • Zeljko Dujic, MD, PhD · University of Split, School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-08
Primary Completion
2022-10-05
Completion
2022-10-05
FDA Drug
Yes

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346562 on ClinicalTrials.gov